These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3501101)

  • 21. Haemophilus influenzae type b disease after rifampin prophylaxis in a day care center: possible reasons for its failure.
    Murphy TV; McCracken GH; Moore BS; Gulig PA; Hansen EJ
    Pediatr Infect Dis; 1983; 2(3):193-8. PubMed ID: 6602974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trimethoprim and rifampin in combination for chemoprophylaxis of household contacts of patients with invasive infections due to Haemophilus influenzae type b.
    Daum RS; Glode MP; Ambrosino D; Halsey N; Goldmann DA; Mather FJ; Russell R; Kamon J; Murray M; Band JD
    Antimicrob Agents Chemother; 1983 Nov; 24(5):658-62. PubMed ID: 6607027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines.
    Pediatrics; 1993 Sep; 92(3):480-8. PubMed ID: 8361814
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of secondary cases of Haemophilus influenzae type b disease.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Dec; 31(50):672-4, 679-80. PubMed ID: 6819447
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b.
    Yogev R; Melick C; Glogowski W
    Antimicrob Agents Chemother; 1982 Mar; 21(3):387-9. PubMed ID: 6980621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is there a place for rifampicin in the treatment of bacterial bronchopulmonary infections?].
    Maesen FP; Buytendijk HJ
    Poumon Coeur; 1970; 26(2):193-7. PubMed ID: 4393036
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemoprophylaxis for haemophilus influenzae type b.
    BMJ; 1991 May; 302(6785):1149. PubMed ID: 1878054
    [No Abstract]   [Full Text] [Related]  

  • 28. American Academy of Pediatrics Committee on Infectious Diseases: Revision of recommendation for use of rifampin prophylaxis of contacts of patients with Haemophilus influenzae infection.
    Pediatrics; 1984 Aug; 74(2):301-2. PubMed ID: 6379591
    [No Abstract]   [Full Text] [Related]  

  • 29. Haemophilus influenzae type b in a nursery school: the value of biotyping.
    Prober CG; Ipp MM; Bannatyne RM
    Pediatrics; 1982 Feb; 69(2):215-8. PubMed ID: 6977129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of chemoprophylaxis to prevent the spread of Hemophilus influenzae B in day-care facilities.
    Broome CV; Mortimer EA; Katz SL; Fleming DW; Hightower AW
    N Engl J Med; 1987 May; 316(19):1226-8. PubMed ID: 3494944
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemoprophylaxis for household contacts of index cases of invasive non-type b Haemophilus influenzae disease.
    Murray DL; Gilsdorf JR
    Pediatr Infect Dis J; 2001 Nov; 20(11):1099-100. PubMed ID: 11734725
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence of anti-microbial resistance among respiratory isolates of Haemophilus influenzae.
    Puri J; Talwar V; Juneja M; Agarwal KN; Gupta HC
    Indian Pediatr; 1999 Oct; 36(10):1029-32. PubMed ID: 10745313
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of salivary concentrations of rifampin and cefaclor: a rationale for chemoprophylaxis of Hemophilus influenzae type b disease.
    Ginsburg CM; McCracken GH
    Clin Pediatr (Phila); 1982 Jul; 21(7):397-9. PubMed ID: 7044641
    [No Abstract]   [Full Text] [Related]  

  • 34. Rifampin prophylaxis for Haemophilus infections.
    Shapiro ED
    J Pediatr; 1981 Oct; 99(4):670-1. PubMed ID: 7277124
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimicrobial susceptibility of Haemophilus influenzae isolates collected from 4 centers in Brazil (1990-2003).
    de Almeida AE; de Filippis I; Ferreira DG; de Abreu AO; Rebelo C; Gemal AL; Marzochi KB
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):57-62. PubMed ID: 16290031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epidemiologic profile of Haemophilus influenzae infection in Tunisia].
    Thabet L; Boutiba I; Kammoun A; Khelif L; Mahjoubi F; Smaoui H; Kechrid A; Ben Redjeb S; Hammami A
    Tunis Med; 2002 Aug; 80(8):469-72. PubMed ID: 12703127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of rifampin-resistant Haemophilus influenzae.
    Nicolle LE; Postl B; Kotelewetz E; Albritton W; Harding GK; Bourgault AM; Ronald AR
    Antimicrob Agents Chemother; 1982 Mar; 21(3):498-500. PubMed ID: 6980623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The activity of the macrolides on Haemophilus influenzae: a critical review].
    Perea EJ
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():60-4. PubMed ID: 9717163
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antimicrobial resistance in Haemophilus influenzae in the city of Havana, Cuba].
    Llanes R; Azahares LE; Pérez MF; Martínez I; Patton AS
    Rev Argent Microbiol; 1996; 28(1):17-21. PubMed ID: 8815456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease.
    McCracken GH; Ginsburg CM; Zweighaft TC; Clahsen J
    Pediatrics; 1980 Jul; 66(1):17-21. PubMed ID: 6967586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.